AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Adjusted R&D Expense — Non-GAAP by Year
Adjusted R&D Expense — Non-GAAP ($M) ($M)
AbbVie Adjusted R&D Expense — Non-GAAP: $18M in FY2025, down 99.8% from a year earlier.
Latest, FY2025
18
Period ended Dec 31, 2025
Change on a year earlier
-99.8%
8,056 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| As adjusted (non-GAAP) | $ | 21,692 | $ | 3,901 | 18.0 | % 11AbbVie Inc.”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Non-GAAP Reconciliations.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adjusted R&D Expense — Non-GAAP ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18 | -99.8% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 8,056 | +14.6% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 7,029 | +9.2% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 6,435 | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie Adjusted R&D Expense — Non-GAAP ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd-adj-exp
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.